Ernexa Therapeutics vs Cartesian Therapeutics
ERNA and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ERNA and RNAC compare
Cartesian Therapeutics is the larger company, worth 66 times as much as Ernexa Therapeutics ($208M against $3.2M).
Ernexa Therapeutics scores higher on the StockData Score (6 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ERNA | RNAC |
|---|---|---|
| Size and price | ||
| Market cap | $3.2M | $208M |
| Share price | $1.93 | $6.89 |
| Change, 1 year | −95.4% | −12.5% |
| Change, 5 years | −100.0% | −92.8% |
| Beta (5Y) | 1.59 | 1.42 |
| Employees | 5 | 75 |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 203× |
| P/B | 0.7× | – |
| FCF yield | −341% | −43.1% (better) |
| Growth | ||
| Revenue growth, 5Y average | – | −30.0% |
| Profitability | ||
| Operating margin | – | −15541% |
| Net margin | – | −12435% |
| FCF margin | – | −8770% |
| Return on equity | −352% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 2.57 | 8.38 (better) |
| Altman Z-score | −56.35 | −5.09 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 29.3% |
| Held by insiders | – | 55.7% |
| Insider net buying, 12 months | $2.0M (better) | −$52.9K |
| Short interest, % of float | – | 14.3% |
Go deeper
- ERNA stock overview
- ERNA income statement
- ERNA valuation and score
- RNAC stock overview
- RNAC income statement
- RNAC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.